Fig. 3From: Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessmentsInvestigator-assessed PFS by clinical variables in (A) the training (N = 846) and (B) the hold-out set (N = 422), and (C) the model incorporating imaging metrics in the training and (D) the hold-out set. CI, confidence interval; HR, hazard ratio; PFS, progression-free survivalBack to article page